Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Organisation › Details

Moderna Inc. (Nasdaq: MRNA)

In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. *

 

Period Start 2018-08-01 renamed
  Group Moderna (Group)
  Predecessor Moderna Therapeutics Inc.
Products Industry mRNA-based drug
  Industry 2 mRNA technology
Persons Person Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)
  Person 2 Kim, Lorence H. (Moderna 201903 CFO)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 200 Technology Square
  City 02139 Cambridge, MA
  Tel +1-617-714-6500
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2020-02-12)
  Currency USD
  Annual sales 60,209,000 (revenue, total, consolidated (2019) 2019-12-31)
  Profit -514,021,000 (2019-12-31)
  Cash 1,103,000,000 (2019-12-31)
     
    * Document for �About Section�: Moderna, Inc.. (6/21/22). "Press Release: Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom". Cambridge, MA.
     
   
Record changed: 2022-09-01

Advertisement

Picture Wirtschaftsförderung Sachsen Life Sciences in Saxony 650x200px

More documents for Moderna (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px




» top